Arvinas (ARVN)

• Market cap: $703M
• 1 day: -0.83%
• 5 days: 1.59%
• 1 month: 27.22%
• 3 months: 26.39%
• 6 months: 7.16%
• Year to date: -49.29%
• 1 year: -63.94%
• 5 years: -53.43%
• 10 years: -40.31%
• Sector: Healthcare
• Industry: Biotechnology

About: Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Employees: 430